We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Head and Neck Cancer Recurrence Detected Earlier by Follow-Up PET/CT

By HospiMedica International staff writers
Posted on 07 Feb 2012
Routine use of positron emission tomography/computed tomography (PET/CT) scanning in head and neck cancer patient follow-up studies has been shown to identify local recurrences before they become clinically apparent and may improve the outcome of subsequent salvage therapy.

The study’s findings were presented January 29, 2012, at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Head and Neck Society (AHNS), American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Nuclear Medicine (SNM), held in Phoenix (AZ, USA).

PET scan is a comparatively new imaging modality and its use as a routine follow up for head and neck cancer patients is controversial. More...
Most head and neck cancer follow-up studies use fluorodeoxyglucose-PET (FDG-PET) scans when recurrence is suspected, but few studies have been conducted to determine the benefit of PET scans in fixed intervals post-treatment.

Researchers in this study reviewed 234 head and neck cancer cases treated with chemoradiation between 2006 and 2010 that also underwent a posttherapy PET/CT scan. The scans identified 15 patients with abnormalities requiring further evaluation, and biopsies showed malignancies in eight of the 15 patients. The other seven cases were false-positives.

All of the patients who had negative PET/CT scans remained disease free in subsequent follow-ups. “With malignancies found in 53% of abnormal scans in this study, our research proves that PET/CT scans are valuable as routine follow-up and as a surveillance method for head and neck cancer patients,” said Yasir Rudha, MD, MBChB, lead author of the study and a researcher from St. John Hospital/Van Elslander Cancer Center (Grosse Pointe Woods, MI, USA). “However, since the rate of false-positives was 46%, caution should be shown when ordering biopsies after abnormal scans to prevent excessive unnecessary biopsies.”

Related Links:

St. John Hospital/Van Elslander Cancer Center




Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Ultrasound System
FUTUS LE
Infant Incubator
OKM 801
Digital X-Ray Detector Panel
Acuity G4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.